Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
Summary
Background: Advanced urothelial cancer has no cure. But only a few chemotherapy drugs have been tested for it. The Co-eXpression ExtrapolatioN (COXEN) model predicts if cells respond to treatment. It may also help determine which drugs fight urothelial cancer based on the characteristics of a tumor. Researchers want to test if this model can choose the best therapy for advanced urothelial cancer within 3 weeks and how tumors respond to the next best therapy. Objective: To test if the COXEN model can choose the best therapy for advanced urothelial cancer within 3 weeks. Eligibility: People ages 18 and older whose urothelial cancer has spread after at least 1 line of chemotherapy Design: Participants will be screened with medical history, physical exam, blood and urine tests, and tumor scans. Participants will provide a tumor sample from a previous surgery and a new biopsy. A needle will remove a small piece of tumor. Participants will repeat screening tests, plus have an electrocardiogram (EKG) and scan. For the scan, they will get an injection of radioactive drug. They will lie in a machine that takes pictures. Participants will take the drugs assigned by the COXEN model. They will have visits every 2-3 weeks. These will include blood and urine tests. Participants will have tumor scans every 8-9 weeks. Participants may have another biopsy. Participants will take the drugs until they can't tolerate the side effects or their cancer worsens. They may be assigned to a second COXEN therapy. Participants will have a follow-up visit 4-5 weeks after their last drug dose. Participants will be contacted by phone every few months until death.
Timeline
- Start
- 2017-03-27
- Primary completion
- 2019-10-23
- Completion
- 2019-10-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | — | — |
| Subject | Asparaginase Escherichia coli source | Unknown | — | — |
| Subject | Axitinib | Small molecule | — | — |
| Subject | Azacitidine | Other / unclassified | — | — |
| Subject | Bendamustine | Small molecule | — | — |
| Subject | Bleomycin | Unknown | — | — |
| Subject | Bortezomib | Small molecule | — | — |
| Subject | Busulfan | Small molecule | — | — |
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Carfilzomib | Other / unclassified | — | — |
| Subject | Chlorambucil | Other / unclassified | — | — |
| Subject | Cisplatin | Other / unclassified | — | — |
| Subject | Cladribine | Small molecule | — | — |
| Subject | Clofarabine | Other / unclassified | — | — |
| Subject | Crizotinib | Small molecule | — | — |
| Subject | Cytarabine | Small molecule | — | — |
| Subject | Dacarbazine | Small molecule | — | — |
| Subject | Dactinomycin | Protein / enzyme biologic | — | — |
| Subject | Daunorubicin | Small molecule | — | — |
| Subject | Decitabine | Small molecule | — | — |
| Subject | Docetaxel | Small molecule | — | — |
| Subject | Doxorubicin | Other / unclassified | — | — |
| Subject | Epirubicin | Small molecule | — | — |
| Subject | Eribulin | Small molecule | — | — |
| Subject | Erlotinib | Small molecule | — | — |
| Subject | Etoposide | Small molecule | — | — |
| Subject | Exemestane | Small molecule | — | — |
| Subject | Floxuridine | Unknown | — | — |
| Subject | Fludarabine | Small molecule | — | — |
| Subject | Gefitinib | Small molecule | — | — |
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Hydroxyurea | Other / unclassified | — | — |
| Subject | Idarubicin | Small molecule | — | — |
| Subject | Ifosfamide | Small molecule | — | — |
| Subject | Imatinib | Small molecule | — | — |
| Subject | Irinotecan | Small molecule | — | — |
| Subject | Ixabepilone | Small molecule | — | — |
| Subject | Lapatinib | Small molecule | — | — |
| Subject | Lomustine | Small molecule | — | — |
| Subject | Mechlor | Unknown | — | — |
| Subject | Melphalan | Small molecule | — | — |
| Subject | Mercapto | Unknown | — | — |
| Subject | Methotrexate | Small molecule | — | — |
| Subject | Mitomycin C | Other / unclassified | — | — |
| Subject | Mitotane | Small molecule | — | — |
| Subject | Mitoxantrone | Small molecule | — | — |
| Subject | Nilotinib | Small molecule | — | — |
| Subject | Oxaliplatin | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | Pazopanib | Small molecule | — | — |
| Subject | Pentostatin | Small molecule | — | — |
| Subject | Romidepsin | Peptide | — | — |
| Subject | Ruxolitinib | Small molecule | — | — |
| Subject | Sorafenib | Small molecule | — | — |
| Subject | Sunitinib | Small molecule | — | — |
| Subject | Tamoxifen | Small molecule | — | — |
| Subject | Temsirolimus | Small molecule | — | — |
| Subject | Teniposide | Small molecule | — | — |
| Subject | Thioguanine | Small molecule | — | — |
| Subject | Thiotepa | Other / unclassified | — | — |
| Subject | Topotecan | Small molecule | — | — |
| Subject | Toremifene | Small molecule | — | — |
| Subject | Tretinoin | Small molecule | — | — |
| Subject | Vandetanib | Small molecule | — | — |
| Subject | Vemurafenib | Small molecule | — | — |
| Subject | Vinblastine | Small molecule | — | — |
| Subject | Vincristine | Small molecule | — | — |
| Subject | Vismodegib | Small molecule | — | — |
| Subject | Vorinostat | Small molecule | — | — |
| Subject | arsenic trioxide | Small molecule | — | — |
| Subject | carmustine | Small molecule | — | — |
| Subject | dasatinib anhydrous | Small molecule | — | — |
| Subject | estramustine | Other / unclassified | — | — |
| Subject | fluorouracil | Small molecule | — | — |
| Subject | streptozocin | Small molecule | — | — |